2025 financial highlights:Cash and cash equivalents totaled €101.1 million as of December 31, 2025Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from IpsenCash runway beyond the end of 20282026 business and pipeline outlook:PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD developmentCCA: Additional Phase 1 cohort data expected mid?year, Phase 2 initiation targeted in 2H26ACLF: Phase 2 initiation with lead asset NTZ anticipated in 2H26, data expected in 2027PSC: Ipsen?led Phase 3 study initiated…